2分鐘暴漲200%!開拓藥業公佈新冠口服藥三期數據,保護率達100%!資金聞聲起舞
開拓藥業剛剛的股價走勢明明白白詮釋了什麼叫“亮瞎你的鈦合金狗眼”!
繼週一暴漲近37%後,開拓藥業今日9:30再度高開近15%報16.06港元,2分鐘後,資金一路猛攻孟打,開拓藥業暴漲220%,報46港元。

消息面上,4月6日,開拓藥業在港交所公吿,公佈了普克魯胺治療輕中症非住院新冠患者III期臨牀試驗(NCT04870606)的關鍵數據結果。

最終分析結果顯示,普克魯胺有效降低新冠患者(主要受Delta和Omicron變異株感染)的住院/死亡率,特別是對於服藥超過7天的全部患者,以及伴有高風險因素的中高年齡新冠患者達到100%保護率,具有統計學顯著性。同時,普克魯胺可以顯著降低新冠病毒載量,改善相關新冠症狀。普克魯胺用藥的安全性也進一步得到驗證(適用於18歲以上成年男女)。
持續更新中……
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.